1. Home
  2. RPGL vs VERU Comparison

RPGL vs VERU Comparison

Compare RPGL & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Republic Power Group Limited Class A Ordinary Shares

RPGL

Republic Power Group Limited Class A Ordinary Shares

BUY

Current Price

$6.88

Market Cap

37.5M

Sector

Technology

ML Signal

BUY

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.29

Market Cap

41.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RPGL
VERU
Founded
2015
1971
Country
Singapore
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
37.5M
41.9M
IPO Year
2022
1996

Fundamental Metrics

Financial Performance
Metric
RPGL
VERU
Price
$6.88
$2.29
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $25.67
AVG Volume (30 Days)
94.7K
★ 205.8K
Earning Date
07-10-2026
08-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $16,296,958.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$21.40
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.21
$2.05
52 Week High
$46.12
$7.33

Technical Indicators

Market Signals
Indicator
RPGL
VERU
Relative Strength Index (RSI) 38.97 41.20
Support Level $0.92 $2.11
Resistance Level $13.06 $2.68
Average True Range (ATR) 6.94 0.15
MACD -3.70 -0.01
Stochastic Oscillator 1.51 18.75

Price Performance

Historical Comparison
RPGL
VERU

About RPGL Republic Power Group Limited Class A Ordinary Shares

Republic Power Group Ltd is a provider of customized ERP software solutions, consulting and technical support services, and peripheral hardware to corporate clients and government agencies, including airports, cruise terminals, and technology, trading, and logistics companies. The Company operates from Singapore and has historically served clients in Singapore and Malaysia, offering ERP systems with functions such as accounting, procurement, workflow automation, real-time monitoring, and capabilities including planning, surveillance, and threat detection. The Company leverages artificial intelligence and modular algorithms to address complex operational requirements and integrates sensors, controls, and other hardware to enable IoT connectivity with autonomous or semiautonomous outcomes.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: